-73%

est. 2Y upside i

HealthcareSeries A

New Lantern accelerates radiology with cloud & AI powered medical image analysis. We're in stealth, and we are actively hiring software engineers. If you're curious and interested in architecting the future of medical imaging & disease diagnosis, we're hiring.

Rank

#2170

Sector

Healthcare AI, Medical Imaging Software

Est. Liquidity

~5Y

Data Quality

Data: Medium

New Lantern presents a moderate upside opportunity for a job seeker, with an estimated 44.75% expected upside over a two-year horizon.

Last updated: March 10, 2026

Bull (20%)+250%

New Lantern successfully expands its AI platform across all major imaging modalities, including mammography and PET/CT, achieving significant market penetration by automating a substantial portion of radiology workflows. This leads to strong customer adoption and retention, pushing revenue to over $50M by 2028 and justifying a $259M+ valuation (3.5x current) at a premium multiple due to its innovative technology and efficiency gains.

Base (35%)+75%

New Lantern continues to grow steadily within its niche, securing additional partnerships and expanding its customer base, but faces persistent competition from incumbents. Revenue reaches approximately $25M by 2028, leading to an acquisition or next funding round at a $129.5M valuation (1.75x current), reflecting solid execution but limited market dominance.

Bear (45%)-70%

Dominant incumbents like GE Healthcare and Microsoft Nuance aggressively enter the AI radiology space with competing solutions, leveraging their existing market share and resources. New Lantern struggles to differentiate and gain significant traction, leading to slower-than-expected growth and a down round or acquisition at a significantly reduced valuation of $22.2M, wiping out most common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

31%

Investors hold $23M in liquidation preferences. In an exit at or below the current $74M valuation, common shareholders would receive a significantly reduced pro-rata share, or potentially nothing if the exit is below $23M.

Dilution Risk

high

As a Series A company, New Lantern will likely require at least 1-2 more significant funding rounds (Series B, C) before an IPO or large acquisition, leading to substantial future dilution for current equity holders.

Secondary Liquidity

none

As an early-stage Series A company, there are currently no active secondary markets or tender offers for New Lantern's equity.

Engineering — 4 roles

Operations — 4 roles

Sales — 1 role

View all 9 open roles at New Lantern →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on New Lantern's data — designed to show you've done your homework.

  • 1

    “How is New Lantern planning to build and defend its competitive moat against dominant incumbents like GE Healthcare and Microsoft Nuance, particularly as they develop their own AI solutions or acquire smaller players?”

  • 2

    “With ~$10M in revenue and a $74M valuation, what are the specific product development and go-to-market strategies planned for the next 12-24 months to achieve the growth necessary for a successful Series B or C round?”

  • 3

    “Given the Series A funding and the typical 5-7 year timeline for liquidity events in healthcare AI, what is the company's strategy for providing employee liquidity, and what are the key milestones that would trigger such opportunities?”

Community

Valuation Sentiment

Our model estimates -73% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.